PharmaCyte Biotech, Inc. filed a Form 4 with the SEC on November 20, 2026, disclosing a November 18, 2026 transaction in which it exchanged Series G Long-Term Warrants for common stock of Q/C Technologies, Inc. (NASDAQ:QCLS) under a Consent and Warrant Exchange Agreement.

Key Highlights

  • Warrant exchange: PharmaCyte Biotech exchanged 851,304 Series G Long-Term Warrants for 4,982,272 shares of Q/C Technologies common stock at $0 cost on November 18, 2026.
  • Exchange price basis: The number of shares issued was determined by dividing the Black-Scholes value of the exchanged warrants by $0.3101 per share, the closing price of common stock on the last trading day prior to execution of the Consent Agreement.
  • Post-transaction common stock ownership: Following the transaction, PharmaCyte beneficially owned 5,152,000 shares of common stock, held directly.
  • Preferred stock maturity extended: Pursuant to the same Consent Agreement, the maturity date of 3,000 shares of Series H Convertible Preferred Stock was extended from March 2, 2027 to September 2, 2027, for no additional consideration.
  • Remaining warrant position: PharmaCyte beneficially owned 13,318,344 Series G Long-Term Warrants following the reported transaction, held directly.
  • Relationship to issuer: PharmaCyte Biotech is identified in the filing as a 10% owner of Q/C Technologies, Inc.

PharmaCyte Biotech's Warrant-for-Stock Exchange Under Consent Agreement

According to the filing, on November 18, 2026, PharmaCyte Biotech, Inc. entered into a transaction with Q/C Technologies, Inc. under a Consent and Warrant Exchange Agreement dated November 15, 2026. Under that agreement, PharmaCyte exchanged 851,304 Series G Long-Term Warrants for 4,982,272 shares of Q/C Technologies common stock, par value $0.001 per share. The filing states the share count was determined based on the Black-Scholes value of the warrants divided by $0.3101 per share, described as the closing price of the common stock on the last trading day prior to execution of the Consent Agreement. The transaction is reported with a price of $0.

The filing notes that the post-transaction beneficial ownership of 5,152,000 shares of common stock includes 169,728 shares acquired as payment of Series G Dividends, which the filing states are exempt from Section 16 of the Securities Exchange Act of 1934 pursuant to Rule 16a-9(a). The Series G Long-Term Warrants that remain outstanding carry an exercise price of $0.3101 per share, subject to adjustment, and are exercisable through May 23, 2029, according to the filing.

In a separate but related action under the same Consent Agreement, the filing discloses that PharmaCyte consented to an amendment extending the maturity date of its 3,000 shares of Series H Convertible Preferred Stock from March 2, 2027 to September 2, 2027, for no additional consideration. The filing states that each share of Series H Convertible Preferred Stock, with a stated value of $1,000, is convertible at the holder's election into approximately 3,225 shares of common stock based on a conversion price of $0.3101 per share, subject to adjustment. The filing further states that any deemed cancellation from the amendment is exempted by Rule 16b-6(d) and also exempt from reporting under Rule 16a-4(d). The Form 4 was signed by Carlos A. Trujillo, Chief Financial Officer, on behalf of PharmaCyte Biotech, Inc.

What Was Disclosed

PharmaCyte Biotech, Inc. reported a November 18, 2026 exchange of 851,304 Series G Long-Term Warrants for 4,982,272 shares of Q/C Technologies common stock, a maturity extension for its Series H Convertible Preferred Stock, and resulting beneficial ownership positions in both securities.